The Thoracic Oncology Group of Australasia (TOGA) presents the thoracic cancer highlights from the 2024 ASCO Annual Meeting. Presenters will discuss the major findings in thoracic cancers presented at this international meeting and the expected influence on local practice.
The second half of the evening will present on the topic ‘Does the latest 5-year data for lorlatinib change the paradigm for lung cancer treatments going forward?’, proudly supported by Pfizer.
If you are unable to attend the session, your registration will give you access to the session recording to view at your convenience.
See the full program.
Chairs
A/Prof Melissa Moore
Medical Oncologist, St Vincent’s Hospital
Melissa is a medical oncologist with sub-specialty interests in cancers of the lung, breast and upper gastrointestinal tract. Her research interests include body composition in cancer patients and the role of exercise.
A/Prof Moore undertook oncology training in Sydney followed by a lab-based PhD investigating the molecular mechanisms of cancer cachexia. She is the local principal investigator of a number of clinical trials for patients with lung cancer and oversees the oncology clinical trials department at St Vincent’s Hospital in Melbourne. She is passionate about increasing clinical trial participation. She is a TOGA Board member and Education Chair.
Dr Rebecca Tay
Medical Oncologist, Royal Hobart Hospital / Icon Cancer Centre
Dr Rebecca Tay is a medical oncologist at the Royal Hobart Hospital and Icon Cancer Centre. Dr Tay completed medical oncology training in Melbourne followed by a clinical research fellowship in lung cancer at The Christie NHS Foundation Trust in Manchester, United Kingdom.
Dr Tay is extensively involved in clinical research as a principal/sub-investigator for several active clinical trials and is the current TOGA Scientific Committee SCLC/mesothelioma co-chair.
Speakers
A/Prof Thomas John
Medical Oncologist, Peter MacCallum Cancer Centre
A/Prof Thomas John is a medical oncologist specialising in Thoracic malignancies and genetics working at the Peter MacCallum hospital in Melbourne. He received his medical degree from Monash University and PhD from University of Melbourne in 2008. He completed a post-doctoral fellowship with Prof F. Shepherd and Prof M. Tsao in Toronto before returning to Melbourne.
A/Prof Jaclyn Yoong
Medical Oncologist | Palliative Care Physician, Northern Health | Monash Health
A/Prof Jaclyn Yoong is a Medical Oncologist and Palliative Care Physician from Melbourne. She works at Northern Health and Monash Health, and her primary interest is in lung cancer care and effective integration with palliative care.
Recently she has also become interested in integrated palliative care for patients with progressive neurological disease.
A/Prof Steven Kao
Staff Specialist, Chris O’Brien Lifehouse
A/Prof Steven Kao is a medical oncologist at the Chris O’Brien Lifehouse. He completed his PhD at the Asbestos Diseases Research Institute and focused his research on predictive and prognostic factors in mesothelioma.
Steven is a keen clinical trialist focusing on thoracic oncology and continues translational research in mesothelioma and lung cancer.
Prof Ben Solomon
Medical Oncologist, Peter MacCallum Cancer Centre
Professor Ben Solomon (MBBS, PhD, FRACP) is a Medical Oncologist at the Peter MacCallum Cancer Centre in Melbourne, Australia. After completing a postdoctoral fellowship at the University of Colorado he returned to Peter MacCallum Cancer Centre in 2006 where he practices as a Medical Oncologist with a focus on clinical and translational research in lung cancer and phase I studies of novel anti-cancer therapies.
Dr Malinda Itchins
Medical Oncologist, Royal North Shore Hospital and Chris O’Brien Lifehouse
Dr Malinda Itchins BMedSci, MBBS(Hons1), PhD, FRACP, is a thoracic medical oncologist at Royal North Shore Hospital, GenesisCare, and North Shore Private and early career researcher and senior clinical lecturer with the University of Sydney.
She is Primary Investigator on several lung cancer clinical trials and her research focus to date has been in patterns of care, the real-world experience, biomarker exploration and drug resistance in lung cancer.
Graham Hall
Consumer Advocate
Graham has been a Patient Advocate for Lung Cancer since his diagnosis in 2018. He started patient advocacy after he saw the disparity with the survival rate and level of care, between his two primary cancers, Prostate and Lung Cancer (ALK positive mutation).
Graham continues to seek out opportunities to help the broader Lung Cancer Community achieve better outcomes for those, like himself, fighting Lung Cancer.
Thank You to Our Sponsors
